news 
Bioptimus Raises $41M to Develop a ‘GPT for Biology’
French AI startup Bioptimus has secured a significant investment of $41 million to further its mission in developing a groundbreaking “GPT for biology” foundation model. This innovative technology has the potential to revolutionize the field of biotechnology, and the funds will be utilized to bolster the company’s platform with a diverse array of data sources covering broader therapeutic areas.
The company aims to achieve this by leveraging multimodal patient data amassed by its parent organization, Owkin, which is a significant advantage in the development process. In addition to this, Bioptimus plans to build further partnerships with the pharmaceutical and biotech sector.
The foundation model will be designed to analyze vast amounts of data from various sources, including images, text, and other modalities, to accelerate research and diagnoses for diseases such as cancer. This technology has far-reaching implications in improving healthcare outcomes and advancing medical research.
Bioptimus’s latest funding round was led by US-based venture capital firm Cathay Innovation, along with support from several other prominent investors, including Sofinnova Partners, Bpifrance, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and a number of angel investors.
The funds will be used to enhance the AI platform with additional data sources covering broader therapeutic areas and build partnerships with pharmaceutical and biotech companies.
Source: techcrunch.com
